In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Natasha Fisher-PearsonKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Medicine, University of Oxford; Oxford, UK.ORCID 0000-0003-2285-1220 Martin J LettTranslational Gastroenterology and Liver Unit, Nuffield Department of Medicine (NDM), University of Oxford; Oxford, UK.ORCID 0000-0002-7230-9264 Isaac W D MaylamKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Medicine, University of Oxford; Oxford, UK.ORCID 0009-0000-4684-6165 Connor J S PhilpTranslational Gastroenterology and Liver Unit, Nuffield Department of Medicine (NDM), University of Oxford; Oxford, UK.ORCID 0009-0003-4190-732X Robert SimmonsImmunocore Ltd.; Abingdon, UK.
Benjamin SwiftCarus Animal Health; Stevenage, UK.
Walter JaokoKAVI-Institute of Clinical Research (KAVI-ICR), University of Nairobi; Nairobi, Kenya.
Freddie KibengoMRC/UVRI & LSHTM Uganda Research Unit (MUL); Entebbe, Uganda.
William KilembeCenter for Family Health Research Zambia (CFHRZ); Lusaka, Zambia.
Eduard J SandersKEMRI-Wellcome Trust Research Programme (KWTRP); Kilifi, Kenya.
Mark C ColesKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Medicine, University of Oxford; Oxford, UK.ORCID 0000-0001-8079-9358 Claire F PearsonKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Medicine, University of Oxford; Oxford, UK.
Paola CicconiThe Jenner Institute, Nuffield Department of Medicine, University of Oxford; Oxford, UK.
Paul KlenermanTranslational Gastroenterology and Liver Unit, Nuffield Department of Medicine (NDM), University of Oxford; Oxford, UK.ORCID 0000-0003-4307-9161 Jethro S JohnsonKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Medicine, University of Oxford; Oxford, UK.ORCID 0000-0001-9155-054X Funding
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MNHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005Wellcome Trust
6 · The paper itselfAbstract
Archaea, the third domain of life, are a gut microbiome constituent, but their role in shaping immunity is poorly understood. Mucosal-associated invariant T (MAIT) cells sense microbial metabolites through their T cell receptor and contribute to antimicrobial defence and barrier homeostasis. Key sources of the major MAIT cell antigen 5-OP-RU within the human gut microbiome are unknown. Analysing microbiomes from UK, Zambian, Kenyan and Ugandan donors, we found strong correlations between archaeal riboflavin biosynthesis and circulating MAIT cell frequency and activation. Stool 5-OP-RU levels correlated with archaeal abundance. Cultures of methanogenic archaea, including the human commensal
Identifiers
PMID42779774
PMCPMC13596232
What OpenQuestion holds
Textmetadata
Read underepoch 390